Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Warnings-26)

In this article we will discuss Durvalumab (Warnings-26)

In this article, we will discuss Durvalumab (Warnings-26). So, let’s get started.

Immune-Mediated Dermatology Reactions: Durvalumab can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens Johnson Syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN), has occurred with PD-1/L-1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or
permanently discontinue Durvalumab depending on severity.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.